Isogenica

Isogenica Limited is a biotechnology company based in Little Chesterford, United Kingdom, that specializes in designing and licensing synthetic antibody libraries and display technologies for antibody discovery. The company offers several systems, including the llamdA System for single-domain antibodies, the Xab System for human antibody fragments, and the 4D Fab System for synthetic human antibodies. Additionally, Isogenica provides peptide and scaffold platforms to facilitate the development of therapeutic peptides aimed at treating diseases. Its proprietary vitro display technology, known as CIS display, is employed to discover biologically active peptides, proteins, and antibodies. The company's innovative small-format antibodies can be utilized to create bispecific and multi-specific biotherapeutics, enhancing targeted drug delivery in applications such as antibody-drug conjugates and cell and gene therapies. Established in 1998 and originally named Pharmacophorix Limited, Isogenica serves pharmaceutical and biotechnology sectors, contributing significantly to advancements in medical research and therapeutic development.

William Eldridge Ph.D

CEO and Board Member

1 past transactions

Karyon-CTT

Acquisition in 2008
Karyon, Ltd. develops peptides into carriers for use in cancer diagnostics, imaging, and therapy. It offers Karyon Targeting Unit, a synthetic peptide that targets specific tumor tissue. The company engages in the areas of cancer biology and cell growth regulation, angiogenesis, biochemistry, peptide chemistry, organic syntheses and immunohistochemistry. Karyon, Ltd. was founded in 2001 and is based in Helsinki, Finland. As of May 6, 2008, Karyon Ltd. operates as a subsidiary of Isogenica Limited.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.